Sponsors (2)
The resolution could boost research attention and funding that benefits CMT patients and researchers, but it may raise patient expectations and lead to modest additional taxpayer-funded research spending.
People with Charcot–Marie–Tooth disease (patients with chronic conditions) could receive greater federal research attention that may accelerate studies and potential future treatments.
Researchers and universities could see increased grant and funding opportunities if agencies respond to findings by restoring or expanding CMT research programs.
Patients and families may develop unrealistic expectations for near-term treatments or cures despite genetic complexity and absence of a confirmed causative gene.
Taxpayers could face modestly higher federal research spending if agencies increase funding to address identified shortfalls.
Based on analysis of 2 sections of legislative text.
Records congressional findings about CMT prevalence, inheritance, many genetic types, lack of a single causative gene, and a decline in federal research funding.
Introduced February 25, 2026 by Josh S. Gottheimer · Last progress February 25, 2026
States congressional findings about Charcot-Marie-Tooth disease (CMT): it damages peripheral nerves, is largely inherited, includes many types (such as CMT4B3), and affects an estimated 126,000 people in the U.S. and 2.6 million worldwide. The resolution also notes that no single causative gene has been identified and that federal research funding for CMT declined from 2021 to 2022.